Misguided Pricing Tactics Delay Access To Medicines, Warns NHS England
Executive Summary
Pharmaceutical companies must not delay patient access to medicine through “salami slicing” pricing strategies, says Blake Dark, commercial medicines director at NHS England.
You may also be interested in...
ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme
Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.